Stem Cell Therapy for Achilles Tendonosis in Runners: Can It Help?

Persistent heel and calf pain that flares with every run and never quite resolves with rest is one of the most frustrating injuries a runner can face. When that pain traces back to chronic, degenerative changes in the Achilles tendon rather than a simple flare-up, it's known as Achilles tendinosis, and it's a common reason runners start researching regenerative options like stem cell therapy for Achilles tendonosis for runners. This article looks at what the condition actually is, how stem cell therapy is thought to work, what the clinical evidence currently shows, how it compares with more established treatments, and what safety and recovery may look like. It's worth saying upfront: stem cell therapy for this specific use remains investigational, not an approved or guaranteed cure, and the evidence base is still early.

What Is Achilles Tendinosis, and Why Do Runners Get It?

Achilles tendinosis and Achilles tendonitis are often used interchangeably, but they describe different things. Tendonitis implies active inflammation, typically short-lived. Tendinosis, by contrast, is a chronic, degenerative process involving disorganized collagen fibers and altered cell activity within the tendon, generally the result of repetitive overload rather than a single injury. Most persistent, weeks-to-months-long Achilles pain in runners falls into this degenerative tendinosis category rather than true tendonitis, which matters because the two are managed somewhat differently.

Runners are especially prone to this injury because of the repetitive load the Achilles tendon absorbs with every stride. A large prospective cohort study following 3,379 runners found that about 4.2% developed Achilles tendinopathy over an average 20-week period, with roughly two-thirds affecting the mid-portion of the tendon and about a quarter to a third at the heel insertion point (Chen et al., Journal of Sport and Health Science, 2024). The same study found men had a higher incidence than women, and a prior history of Achilles tendinopathy was the strongest predictor of developing it again. For runners already managing this cycle, stem cell therapy for runners has become one of several options discussed alongside more conventional rehabilitation.

How Is Achilles Tendinosis Traditionally Treated?

Before considering any regenerative option, it helps to understand what's already established as effective. Load-based rehabilitation, particularly eccentric calf-strengthening exercises (the Alfredson protocol is the best-known example), is currently the best-supported first-line treatment. A 2026 systematic review and meta-analysis of 21 randomized controlled trials involving 994 participants found that eccentric exercise programs were associated with meaningful improvements in pain and measurable changes in tendon structure, including thickness and vascularity (Yuan et al., BMC Musculoskeletal Disorders, 2026).

Beyond structured loading, common conservative measures include activity modification, relative rest from aggravating impact, NSAIDs for symptom control, and physical therapy focused on gradual load progression. For runners who don't improve after several months of consistent conservative care, some clinicians consider extracorporeal shockwave therapy (ESWT) or, in recalcitrant cases, surgical debridement. It's this group of runners, those who have given conservative care a genuine trial without lasting relief, who most often start exploring orthobiologic and stem cell options.

What Is Stem Cell Therapy, and How Might It Help Achilles Tendons?

In this context, stem cell therapy generally refers to an injection of mesenchymal stem cells (MSCs), most often sourced from the patient's own bone marrow, though adipose (fat) tissue is another possible source. These are not being used to literally "grow" a new tendon. Current mechanistic research suggests MSCs act mainly through paracrine signaling, meaning they release growth factors and extracellular vesicles that may help modulate local inflammation and recruit the body's own repair processes, rather than the injected cells themselves becoming new tendon tissue (Dias & Anderson, Cells, 2026). This is a meaningfully different, and more modest, mechanism than the "regeneration" framing sometimes used in marketing materials.

How the Procedure Generally Works

In the one published human trial specific to this condition, bone marrow was harvested from the pelvis, the mesenchymal stem cells were isolated and expanded in a lab over roughly four to six weeks, and the resulting cell product was then injected into the affected portion of the tendon under ultrasound guidance (Goldberg et al., BMJ Open, 2018). This general sequence, harvest, laboratory processing, and image-guided injection, reflects the broader process used in MSC-based orthobiologic protocols, though specific clinic procedures can vary.

What Does the Evidence Actually Show for Stem Cell Therapy for Achilles Tendinosis?

Here it's important to be direct: the evidence for achilles tendinosis stem cell therapy specifically is thin. As of this writing, only one human trial has tested culture-expanded mesenchymal stem cells specifically for chronic Achilles tendinopathy, a small, single-arm, open-label phase IIa proof-of-concept study of just 10 patients who had already failed conservative treatment (Goldberg et al., Scientific Reports, 2024). Its primary purpose was to establish safety, and on that front, the trial reported no serious adverse reactions or important medical events over 24 weeks of follow-up. Secondary outcome measures also improved from baseline, including pain and function scores (MOXFQ, VISA-A, and VAS), but because there was no control group, these improvements cannot be cleanly separated from natural healing, physical therapy the patients may have continued, or a placebo response. This is a preliminary safety signal, not proof of efficacy.

The best comparative, RCT-level evidence available involves a related orthobiologic: adipose-derived stromal vascular fraction (SVF), a tissue fraction that contains stem cells among other cell types. A randomized trial compared SVF injection against PRP for recalcitrant Achilles tendinopathy and found SVF produced faster early improvement in pain and function scores at 15 and 30 days, though the two groups converged by later follow-up, with both treatments considered safe (Usuelli et al., Knee Surgery, Sports Traumatology, Arthroscopy, 2018). A subsequent systematic review that specifically searched for Achilles-related cell therapy trials identified this same study as the only Achilles-specific randomized trial available, and confirmed no statistically significant difference between the SVF and PRP groups at six months, concluding that no firm efficacy recommendation can yet be made for stem cell therapy in Achilles tendinopathy (Mirghaderi et al., Journal of Experimental Orthopaedics, 2022).

It's also worth understanding how the more-studied "cousin" therapy, PRP, has fared, since it provides useful context. One meta-analysis of 8 RCTs and 526 patients found no statistically significant benefit for PRP over placebo on most outcome measures, with only a modest pain benefit reaching significance at 12 weeks (Vithran et al., Journal of Clinical Medicine, 2023). A more recent 2025 meta-analysis reported more favorable pooled results for PRP (Ahmed et al., Cureus, 2025). Taken together, these two reviews illustrate real heterogeneity in the literature rather than a settled answer, even for the orthobiologic with the largest evidence base.

What Do Medical Guidelines Recommend?

No major medical society currently recommends stem cell or MSC injection therapy as standard care for Achilles tendinosis. Reviewers who have synthesized the available cell-therapy literature across tendon disorders, including the Achilles, consistently conclude that larger, controlled trials are still needed before efficacy and long-term safety can be confirmed (Mirghaderi et al., Journal of Experimental Orthopaedics, 2022; Cho et al., Annals of Rehabilitation Medicine, 2021). Eccentric, load-based exercise remains the guideline-supported first-line approach discussed above, and it is the treatment with the deepest and most consistent evidentiary support of any option covered in this article.

How Does Stem Cell Therapy Compare With PRP and Other Options?

Viewed side by side, the three most-discussed options for Achilles tendinosis sit at different points on the evidence spectrum. Eccentric exercise has the strongest, most consistent RCT-level support and remains the established first-line approach. PRP has a much larger body of research than stem cell therapy but shows genuinely mixed results depending on which meta-analysis is consulted. Stem cell and SVF-based therapy sits at the earliest stage: a promising early safety signal and one small comparative RCT, but not yet the kind of large, controlled, Achilles-specific trial needed to draw firm efficacy conclusions. None of this means stem cell therapy doesn't work; it means the evidence needed to say so with confidence doesn't yet exist, and it's important that runners weighing their options understand that distinction rather than treating "regenerative medicine" as a single, uniformly proven category.

Is Stem Cell Therapy for Achilles Tendinosis Safe?

Across the available data, the safety signal for cell-based orthobiologic injections is reassuring, though still based on limited sample sizes. In the single dedicated Achilles MSC trial, no serious adverse reactions occurred over 24 weeks (Goldberg et al., Scientific Reports, 2024). A broader systematic review of 22 clinical studies and 658 patients receiving cell therapy across various tendon sites likewise reported that almost all studies found no serious adverse events or immunologic reactions (Mirghaderi et al., Journal of Experimental Orthopaedics, 2022). Reported issues tend to be minor and expected, such as temporary soreness at the injection site or at the bone marrow harvest site. That said, because the available studies are small and short-term, long-term safety data and rare-event risks are not yet well characterized, which is part of why this remains an investigational approach rather than routine care.

What Does Recovery Typically Look Like?

Recovery expectations should be set cautiously, since they are drawn from a small trial with a defined follow-up window rather than long-term outcome data. In the phase IIa safety trial, patients were followed for 24 weeks, during which pain and function scores were associated with improvement from baseline (Goldberg et al., Scientific Reports, 2024). Individual recovery timelines vary considerably, and structured rehabilitation, particularly continued eccentric loading, generally remains part of a comprehensive recovery plan rather than something stem cell injection would be expected to replace.

Frequently Asked Questions

What is Achilles tendinosis, and how is it different from tendonitis?

Tendinosis is a chronic, degenerative condition involving disorganized collagen and altered tendon cell activity, typically from repetitive overload. Tendonitis, in contrast, implies active inflammation and is usually shorter-lived. Persistent Achilles pain lasting weeks to months in runners is more often tendinosis than true tendonitis.

How common is Achilles tendinosis in runners?

A large prospective cohort study of 3,379 runners found about 4.2% developed Achilles tendinopathy over an average 20-week follow-up, with midportion involvement roughly twice as common as insertional involvement, and men affected somewhat more often than women (Chen et al., Journal of Sport and Health Science, 2024).

What does stem cell therapy for runners actually involve?

It typically involves harvesting a patient's own mesenchymal stem cells, most often from bone marrow, expanding them in a lab, and injecting them into the affected tendon under ultrasound guidance. Current research suggests these cells work mainly through paracrine signaling, releasing factors that may help modulate inflammation and support the body's own repair activity, rather than directly regenerating tendon tissue (Dias & Anderson, Cells, 2026).

Is there clinical evidence that achilles tendinosis stem cell therapy helps?

The evidence is preliminary. Only one small, uncontrolled, 10-patient safety trial has specifically tested MSC injection for Achilles tendinopathy, and while it reported improved pain and function scores alongside a favorable safety profile, the lack of a control group means those improvements cannot be confidently attributed to the injection alone (Goldberg et al., Scientific Reports, 2024). The best comparative RCT evidence involves the related SVF therapy against PRP, which showed faster early improvement with SVF that converged with PRP by six months (Usuelli et al., Knee Surgery, Sports Traumatology, Arthroscopy, 2018).

How does stem cell therapy compare to PRP for Achilles tendinosis?

PRP has a larger evidence base but shows inconsistent results between meta-analyses, with one finding no significant benefit over placebo on most measures (Vithran et al., Journal of Clinical Medicine, 2023) and another reporting more favorable outcomes (Ahmed et al., Cureus, 2025). The one head-to-head RCT comparing SVF (a stem-cell-containing therapy) to PRP found SVF produced faster early relief, with scores converging by later follow-up (Usuelli et al., Knee Surgery, Sports Traumatology, Arthroscopy, 2018).

Is stem cell therapy for Achilles tendinosis safe?

Available data suggest a favorable short-term safety profile, with no serious adverse reactions reported in the dedicated Achilles MSC trial (Goldberg et al., Scientific Reports, 2024) and a broader review of 658 tendon-therapy patients finding almost no serious adverse events overall (Mirghaderi et al., Journal of Experimental Orthopaedics, 2022). Long-term safety data remain limited given the small size of existing studies.

Is stem cell therapy FDA-approved for Achilles tendinosis?

No. No stem cell product is currently FDA-approved for Achilles tendinopathy or tendinosis, and its use for this indication remains investigational.

What is the first-line treatment for Achilles tendinosis in runners?

Eccentric, load-based calf-strengthening exercise is the treatment with the strongest and most consistent supporting evidence, associated with improved pain and measurable changes in tendon structure across a large meta-analysis of 21 randomized trials (Yuan et al., BMC Musculoskeletal Disorders, 2026).

How long does recovery take after stem cell injection for the Achilles tendon?

The only dedicated trial followed patients for 24 weeks, during which pain and function scores were associated with improvement (Goldberg et al., Scientific Reports, 2024), but individual recovery varies, and this window doesn't capture longer-term outcomes. Continued rehabilitation, including eccentric loading, generally remains part of the recovery process.

Who might be a candidate for exploring stem cell therapy for Achilles tendinosis?

Runners with persistent, chronic Achilles tendinosis who have completed a genuine trial of conservative care, including structured eccentric loading, without lasting relief may be reasonable candidates to discuss regenerative options with a qualified provider. Because the evidence base remains early, candidacy should be determined through a personalized evaluation rather than a standardized protocol.

Key Takeaways

• Achilles tendinosis is a chronic, degenerative tendon condition, distinct from acute tendonitis, and is common among runners due to repetitive loading.
• Eccentric exercise remains the best-supported, guideline-favored first-line treatment for Achilles tendinosis.
• Evidence for stem cell therapy for Achilles tendonosis for runners is still early: only one small, uncontrolled safety trial exists specifically for MSC injection in this condition, alongside one comparative RCT involving the related SVF therapy against PRP.
• Available safety data across small studies are reassuring, but no stem cell product is FDA-approved for this indication, and long-term outcome data are not yet available.
• Runners considering this option should discuss it as part of a broader, personalized recovery plan with a qualified provider, not as a stand-alone or guaranteed fix.

Next Steps

Runners weighing regenerative options after conservative care hasn't resolved their symptoms can start with a personalized stem cell therapy and regenerative medicine consultation at Humanaut Health to review their specific case against the current evidence. Humanaut Health has also covered the evidence for stem cell therapy for knee pain and stem cell therapy for sciatica for those exploring regenerative medicine for other chronic pain conditions.